Verseon
Overview
Verseon was founded in 2002. Its proprietary drug discovery platform, developed entirely in-house, is the product of over ten years of research and development.
Features
The company’s platform is the first systematic, computationally-driven solution to achieve the molecular modelling accuracy necessary for rapid and cost-effective drug discovery. Verseon plans to use its platform to establish a diversified discovery pipeline across multiple disease areas. Current drug programs include anticoagulation, diabetic macular edema, hereditary angioedema, and oncology (solid tumors).STO Details
Pre-sale
- Pre-sale start date TBA
- Pre-sale end date TBA
- Pre-sale token supply —
Token Sale
- STO start date TBA
- STO end date TBA
- STO token supply —
- Soft cap TBA
- Hard cap size TBA
Token details
- Ticker VIAT
- Type ERC20
- Additional Token Emission No
- Accepted Currencies —
- Token distribution Smart Contract
Legal
- Country Limitations —
- Registration Country United States
- Registration Year 2002
Rating Review and Analytics
- Investment Rating —
- Traction Low
- Risk Score —
Verseon Contacts
TBA TBA
- Start STO TBA
- End STO TBA
- Funding type —
- Token VIAT
- Price —
- Minimum investment —
- Product Type Digital Asset
- KYC Yes
STOs that might interest you
- Status TBA
- Traction Low
- Risk Score —
- Registration Year —
- Status TBA
- Traction Low
- Risk Score —
- Registration Year —
